Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) announced its earnings results on Friday. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.17), Zacks reports. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The firm had revenue of $4.60 million during the quarter, compared to analyst estimates of $19.04 million. During the same quarter in the previous year, the business earned ($0.42) earnings per share. The business's quarterly revenue was down 57.8% compared to the same quarter last year.
Recursion Pharmaceuticals Stock Down 12.3 %
Shares of NASDAQ RXRX traded down $0.92 during mid-day trading on Monday, reaching $6.59. The company had a trading volume of 25,551,746 shares, compared to its average volume of 26,089,264. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. Recursion Pharmaceuticals has a twelve month low of $5.60 and a twelve month high of $12.93. The stock's 50 day moving average is $7.71 and its 200-day moving average is $7.09. The stock has a market capitalization of $2.57 billion, a PE ratio of -4.31 and a beta of 0.86.
Analysts Set New Price Targets
Several research firms have weighed in on RXRX. Cowen reiterated a "hold" rating on shares of Recursion Pharmaceuticals in a research report on Friday. KeyCorp decreased their target price on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating for the company in a research report on Wednesday, January 8th. Needham & Company LLC reissued a "buy" rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Thursday, February 6th. Finally, Leerink Partners decreased their price objective on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a research report on Friday. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $8.25.
Check Out Our Latest Report on RXRX
Recursion Pharmaceuticals Company Profile
(
Get Free Report)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
See Also
Before you consider Recursion Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.
While Recursion Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
